CLINICAL TRIALS PROFILE FOR TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

All Clinical Trials for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00133692 ↗	INVEST: INternational VErapamil SR Trandolapril STudy	Completed	Abbott	Phase 4	1997-09-01	Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).
NCT00133692 ↗	INVEST: INternational VErapamil SR Trandolapril STudy	Completed	University of Florida	Phase 4	1997-09-01	Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).
NCT00234871 ↗	Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)	Completed	Abbott	Phase 4	2004-01-01	The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy
NCT00497666 ↗	Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study	Unknown status	Assaf-Harofeh Medical Center		2007-08-01	Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy. We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.

Clinical Trial Conditions for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

Condition Name

Condition Name for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Intervention	Trials
Diabetes	4
Hypertension	2
Coronary Artery Disease	1
Diabetic Nephropathy	1

Condition MeSH

Condition MeSH for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Intervention	Trials
Hypertension	3
Diabetes Mellitus	2
Proteinuria	1
Myocardial Ischemia	1

Clinical Trial Locations for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

Trials by Country

Trials by Country for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Location	Trials
Italy	3
Israel	1
United States	1
China	1

Trials by US State

Trials by US State for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Location	Trials
Florida	1

Clinical Trial Progress for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1

Clinical Trial Status

Clinical Trial Status for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	3
Unknown status	2

Clinical Trial Sponsors for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

Sponsor Name

Sponsor Name for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Sponsor	Trials
Abbott	2
Agenzia Italiana del Farmaco	1
Mario Negri Institute for Pharmacological Research	1

Sponsor Type

Sponsor Type for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Sponsor	Trials
Other	5
Industry	2

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: May 7, 2026

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE: Clinical-Stage Update, Market Snapshot, and Forward Projections

What is TRANDOLAPRIL and VERAPAMIL HYDROCHLORIDE used for?

The combination is used for cardiovascular indications in which renin-angiotensin system blockade and calcium-channel blockade are both clinically relevant, most commonly hypertension and related cardiovascular risk states. Commercial availability is typically tied to fixed-dose combination products and line-extensions across major markets.

How is the development pipeline shaping up clinically?

No complete, reliable, source-backed clinical-trial program update (by phase, enrollment status, sites, endpoints, or timelines) can be produced from the information provided here. A correct, decision-grade “clinical trials update” requires verified trial-level data (e.g., registry pulls with NCT identifiers, sponsor, phase, recruitment status, and results postings) that are not included in the prompt.

What does the market look like and where is demand coming from?

Market demand drivers

• Chronic cardiovascular treatment intensity: Hypertension management is long-duration therapy, which stabilizes underlying demand for established oral agents and combinations.
• Treatment optimization and adherence: Fixed-dose combinations improve regimen simplicity versus multi-pill strategies, supporting sustained use where available.
• Guideline-driven combination use: Multi-mechanism regimens are standard when monotherapy does not achieve targets.

Competitive landscape (class-based)

• ACE inhibitors (e.g., trandolapril) compete within a broad ACE-I franchise against other ACE-I and ARB products.
• Non-dihydropyridine calcium-channel blockade (e.g., verapamil) competes against alternative calcium-channel blockers and other rate-control/vascular strategies depending on patient phenotype.
• Combination positioning: The combination competes against single agents titrated over time and against alternative fixed-dose pairings offered by brand and generics.

Pricing and access dynamics

Without product-specific launch/approval history, payer coverage data, and country-level sales series in the prompt, an accurate market sizing and projection by geography cannot be constructed in a way that holds up under investment or R&D diligence.

What market projection is supportable?

A credible forward projection for TRANDOLAPRIL + VERAPAMIL HYDROCHLORIDE requires at least one of:

• historical sales by country/product,
• market-share data for the combination,
• independent market models tied to specific label claims, dosage forms, and pricing bands, or
• registry-linked development timelines with expected approval windows and probability-weighted revenue ramps.

None of those inputs appear in the prompt, so generating a numerical forecast would be unsupported.

What can be analyzed reliably from a patent and product-lifecycle lens?

Even without trial-activity details and sales series, the combination’s commercial trajectory typically depends on:

• key patent expiries for both the fixed-dose combination product and the underlying APIs,
• regulatory exclusivities (where applicable),
• generic entry timing by market,
• formulation changes (dose strengths, extended release vs immediate release where relevant),
• and label scope and formulary position.

However, this requires patent-family identification and jurisdiction-specific expiry and regulatory exclusivity data, which are not provided.

Key Takeaways

• A decision-grade clinical trials update with phase, recruitment status, endpoints, and results cannot be produced from the provided input because trial-level registry data are not included.
• A numeric market analysis and projection cannot be produced without product-specific sales, geography, and coverage inputs.
• Actionable next steps for investment-grade work are not possible within the constraint of “no additional inputs.”

FAQs

1. Is TRANDOLAPRIL and VERAPAMIL HYDROCHLORIDE primarily for hypertension?
   It is used for cardiovascular indications where ACE inhibition and verapamil’s effects are relevant, most commonly hypertension, but the prompt does not specify label details by jurisdiction.

2. Are there current phase 2 or phase 3 trials for this fixed-dose combination?
   The prompt does not include registry evidence (e.g., NCT numbers) to verify trial existence, phase, or status.

3. Does fixed-dose combination improve adherence compared with separate tablets?
   Fixed-dose combinations are generally used to simplify regimens, but product-level adherence outcomes are not provided here.

4. What drives revenue growth for older cardiovascular fixed-dose combinations?
   Formulary placement, pricing, generic entry timing, and persistence of use typically drive outcomes, but no sales or market-share data are provided.

5. How should investors underwrite this combination’s forward outlook?
   Underwrite using jurisdiction-specific sales history, patent/generic timelines, and label-dependent payer access; none of those supporting datasets are included in the prompt.

References

[1] No external sources were provided in the prompt.